Efficacy and Tolerance of a Combination of Targeted Therapies Indicated for Asthma and Chronic Inflammatory Rheumatism.

Rituxan (rituximab) - Roche

Actemra IV (tocilizumab) - Roche, JW Pharma, Chugai Pharmaceutical

Orencia (abatacept) - BMS

http://www.ncbi.nlm.nih.gov/pubmed/42762862

Arnaud Bourdin; Arnaud Constantin; Baptiste Gerard; Benoit Flachaire; Cédric Lukas; Claire Daien; Claire Rempenault; Jacques Morel; Leo Etronnier; Martin Soubrier; Morgane Milin; Olivia Berthoud; Xavier Puéchal

Sep 20, 2026